Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2016.06.047PMID 27416556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.

  2016cited by this paper
• Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.

  2016cited by this paper
• Parkin induces G2/M cell cycle arrest in TNF-α-treated HeLa cells.

  2015cited by this paper
• The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1

  2015cited by this paper
• Oral cavity cancer incidence and mortality in China, 2010.

  2015cited by this paper
• Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis

  2015cited by this paper
• Quercetin Inhibits Proliferation and Drug Resistance in KB/VCR Oral Cancer Cells and Enhances Its Sensitivity to Vincristine

  2015cited by this paper
• Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma

  2015cited by this paper
• Broad targeting of angiogenesis for cancer prevention and therapy

  2015cited by this paper
• Chemotherapy and Chemoprevention by Thiazolidinediones

  2015cited by this paper
• 1118‐20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β‐catenin pathway and receptor tyrosine kinases

  2015cited by this paper
• International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site.

  2014cited by this paper
• Apoptosis and Molecular Targeting Therapy in Cancer

  2014cited by this paper
• Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.

  2014cited by this paper
• DLJ14, a novel chemo‐sensitization agent, enhances therapeutic effects of adriamycin against MCF‐7/A cells both in vitro and in vivo

  2014cited by this paper
• Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression.

  2014cited by this paper
• Targeting the ABCG2‐overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists

  2013cited by this paper
• PPARγ signaling and metabolism: the good, the bad and the future

  2013cited by this paper
• Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies.

  2013cited by this paper
• A comparative study of microvessel density in squamous cell carcinoma of the oral cavity and lip.

  2012cited by this paper
• Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

  2012cited by this paper
• The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

  2012cited by this paper
• The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.

  2012cited by this paper
• Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).

  2011cited by this paper
• Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.

  2010cited by this paper
• Microtubules and resistance to tubulin-binding agents

  2010cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARγ activation by troglitazone

  2010cited by this paper
• Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.

  2010cited by this paper
• Microtubules and resistance to tubulin-binding agents

  2010cited by this paper
• Survival and quality of life of patients with oral and oropharyngeal cancer at 1-year follow-up of tumor resection

  2010cited by this paper
• Global epidemiology of oral and oropharyngeal cancer.

  2009cited by this paper
• Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.

  2009cited by this paper
• Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway

  2009cited by this paper
• Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways

  2009cited by this paper
• Survival following primary surgery for oral cancer.

  2009cited by this paper
• PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis

  2008cited by this paper
• The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

  2008cited by this paper
• PI3K/PTEN signaling in tumorigenesis and angiogenesis.

  2008cited by this paper
• An overview of cancer multidrug resistance: a still unsolved problem

  2008cited by this paper
• Synergy between PPARgamma ligands and platinum-based drugs in cancer.

  2007cited by this paper
• Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.

  2007cited by this paper
• Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer

  2007cited by this paper
• Targeting the cell cycle: a new approach to cancer therapy.

  2005cited by this paper
• Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases.

  2004cited by this paper
• Coupling cell division and cell death to microtubule dynamics.

  1997cited by this paper

• A biomimetic liposome platform targeting non-small cell lung cancer to modulate the inflammatory and metabolic microenvironment for enhanced therapy

  2025cites this paper
• Dual function of activated PPARγ by ligands on tumor growth and immunotherapy

  2024cites this paper
• Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells

  2024cites this paper
• The mechanism of EGFL7 regulating neovascularization in diabetic retinopathy through the PI3K/AKT/VEGFA pathway.

  2024cites this paper
• The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis

  2020cites this paper
• Hispidulin: A promising flavonoid with diverse anti-cancer properties.

  2020cites this paper
• Rosiglitazone binds to RXRα to induce RXRα tetramerization and NB4 cell differentiation.

  2020cites this paper
• microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway.

  2019cites this paper
• Drug Repurposing for Retinoblastoma: Recent Advances.

  2019cites this paper
• PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma

  2019cites this paper
• Glucocorticoids attenuate the sensitivity of glucocorticoid-resistant lymphoid cells to doxorubicin via reduction in OCTN2

  2019cites this paper
• The potential role of P.gingivalis in gastrointestinal cancer: a mini review

  2019cites this paper
• New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers.

  2018cites this paper
• Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme.

  2018cites this paper
• Physcion 8‐O‐β‐Glucopyranoside Exerts Anti‐Tumor Activity Against Non‐Small Cell Lung Cancer by Targeting PPARγ

  2018influential citation
• Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.

  2018cites this paper
• Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators

  2018cites this paper
• SFRP5 is a target gene transcriptionally regulated by PPARγ in 3T3-L1 adipocytes.

  2018cites this paper
• DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo.

  2017cites this paper